Reply to Lipworth and Chan

Guy Brusselle; Sebastian Riemann

doi:10.1164/rccm.202305-0792le

Reply to Lipworth and Chan

Guy Brusselle^*, Sebastian Riemann

^*Corresponding author for this work

Epidemiology

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

12 Downloads (Pure)

Original language	English
Pages (from-to)	211-212
Number of pages	2
Journal	American Journal of Respiratory and Critical Care Medicine
Volume	208
Issue number	2
DOIs	https://doi.org/10.1164/rccm.202305-0792le
Publication status	Published - 15 Jul 2023

Bibliographical note

Funding Information:
Supported by AstraZeneca and Amgen Inc.

Funding Information:
Supported by a grant from AstraZeneca for clinical studies with tezepelumab as part of the WAYPINT trial in patients with chronic rhinosinusitis with nasal polyposis and in the BISA trial with benralizumab in patients with severe eosinophlic asthma, as well as payment for giving talks (B.L.). Also, supported by Sanofi/Regeneron for a clinical study (DISA) in severe asthma with dupilumab and also the SINUS 24 study with dupilumab in patients with chronic rhinosinusitis and nasal polyposis, as well as payment for talks (B.L.).

Access to Document

10.1164/rccm.202305-0792leLicence: CC BY-NC-ND

rccm.202305-0792leFinal published version, 600 KBLicence: CC BY-NC-ND

Cite this

@article{d83e0ef389584169b696cce5688a4579,

title = "Reply to Lipworth and Chan",

author = "Guy Brusselle and Sebastian Riemann",

note = "Funding Information: Supported by AstraZeneca and Amgen Inc. Funding Information: Supported by a grant from AstraZeneca for clinical studies with tezepelumab as part of the WAYPINT trial in patients with chronic rhinosinusitis with nasal polyposis and in the BISA trial with benralizumab in patients with severe eosinophlic asthma, as well as payment for giving talks (B.L.). Also, supported by Sanofi/Regeneron for a clinical study (DISA) in severe asthma with dupilumab and also the SINUS 24 study with dupilumab in patients with chronic rhinosinusitis and nasal polyposis, as well as payment for talks (B.L.).",

year = "2023",

month = jul,

day = "15",

doi = "10.1164/rccm.202305-0792le",

language = "English",

volume = "208",

pages = "211--212",

journal = "American Journal of Respiratory and Critical Care Medicine",

issn = "1073-449X",

publisher = "American Thoracic Society",

number = "2",

}

TY - JOUR

T1 - Reply to Lipworth and Chan

AU - Brusselle, Guy

AU - Riemann, Sebastian

N1 - Funding Information: Supported by AstraZeneca and Amgen Inc. Funding Information: Supported by a grant from AstraZeneca for clinical studies with tezepelumab as part of the WAYPINT trial in patients with chronic rhinosinusitis with nasal polyposis and in the BISA trial with benralizumab in patients with severe eosinophlic asthma, as well as payment for giving talks (B.L.). Also, supported by Sanofi/Regeneron for a clinical study (DISA) in severe asthma with dupilumab and also the SINUS 24 study with dupilumab in patients with chronic rhinosinusitis and nasal polyposis, as well as payment for talks (B.L.).

PY - 2023/7/15

Y1 - 2023/7/15

UR - http://www.scopus.com/inward/record.url?scp=85164846515&partnerID=8YFLogxK

U2 - 10.1164/rccm.202305-0792le

DO - 10.1164/rccm.202305-0792le

M3 - Comment/Letter to the editor

C2 - 37279365

AN - SCOPUS:85164846515

SN - 1073-449X

VL - 208

SP - 211

EP - 212

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

IS - 2

ER -

Reply to Lipworth and Chan

Bibliographical note

Access to Document

Other files and links

Cite this